Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 5Neoplasm Metastasis 2Vomiting 1Urinary Bladder Neoplasms 1TP53 Y220C Mutation 1Solid Tumors 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Nausea 1Myofibroma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Carcinoma 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Cancer 1Adenocarcinoma of Lung 1

Interventions

Tablets 1LFA102 monoclonal antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Myofibroma × Tablets × Clear all
NCT03156127 2017-08-10

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

Boryung Pharmaceutical Co., Ltd

Phase 1 Withdrawn

Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡